Advanced genetic platforms incorporating sophisticated bioinformatics techniques have enhanced our ability to identify SNPs and bio-markers involved in the genetics of alcoholism including risk factors for the development and progression of illness and have provided invaluable insight into the molecular and cellular mechanisms underlying the pathophysiology of alcoholism and the addictions. This insight has contributed to the development of the first targeted, clinically-validated and FDA approved drug treatments for alcoholism. The field will continue to advance through the use of next generation sequencing (whole genome or exome) which will yield additional valuable information on the location and description of genes contributing to alcoholism, enabling the identification of specific and recurring mutations of single genes impacting upon alcoholism-related phenotypes such as tolerance, withdrawal sensitivity, and craving which may provide novel therapeutic targets for future interventions. A current list of clinically relevant genetic biomarkers from brain in alcoholism are summarized and incorporated into high resolution chromosome ideograms (850 band level) to facilitate research, diagnostic testing and genetic counseling options for families in the clinical setting. The location of the 337 genes now
